Page last updated: 2024-08-05 11:09:14

triazene derivative

A nitrogen molecular entity resulting from the formal substitution of one or more of the hydrogens of triazene.

ChEBI ID: 72573

Members (4)

MemberDefinitionRole
5-(3-methyl-1-triazeno)imidazole-4-carboxamideA monocarboxylic acid amide that is dacarbazine in which one of the methyl groups is replaced by a hydrogen. It is the active metabolite of dacarbazine, and is also produced by spontaneous hydrolysis of temozolomide in the body.MTIC
dacarbazineA monocarboxylic acid amide that is 1H-imidazole-4-carboxamide which is substituted at position 5 by a 3,3-dimethyltriaz-1-en-1-yl group. It is used for the treatment of metastatic malignant melanoma, and in combination with other drugs for the treatment of Hodgkin's disease and soft-tissue sarcoma.dacarbazine
diminazeneA triazene derivative that is triazene in which each of the terminal nitrogens is substituted by a 4-carbamimidoylphenyl group.diminazene
temozolomideAn imidazotetrazine that is 3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine which is substituted at positions 3, 4, and 8 by methyl, oxo, and carboxamide groups, respectively. A prodrug for MTIC (5-(3-methyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide, formed by spontaneous hydrolysis of temozolomide in the body), it is used as an oral alkylating agent for the treatment of newly diagnosed malignant glioblastoma multiforme (concomitantly with radiotherapy) and malignant melanoma.temozolomide

Research

Studies (6,586)

TimeframeStudies, Drugs in This Class (%)All Drugs %
pre-1990219 (3.33)18.7374
1990's290 (4.40)18.2507
2000's1,239 (18.81)29.6817
2010's3,354 (50.93)24.3611
2020's1,484 (22.53)2.80

Study Types

Publication TypeStudies, Drugs in This Class (%)All Drugs (%)
Trials855 (12.53%)5.53%
Reviews645 (9.45%)6.00%
Case Studies553 (8.11%)4.05%
Observational22 (0.32%)0.25%
Other4,747 (69.58%)84.16%